Teva Pharmaceutical Industries Limited (TEVA)
| Market Cap | 36.71B +93.4% |
| Revenue (ttm) | 17.26B +4.3% |
| Net Income | 1.41B |
| EPS | 1.21 |
| Shares Out | 1.16B |
| PE Ratio | 26.03 |
| Forward PE | 11.75 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,290,497 |
| Open | 31.38 |
| Previous Close | 31.50 |
| Day's Range | 31.26 - 31.91 |
| 52-Week Range | 12.47 - 37.35 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 37.38 (+18.59%) |
| Earnings Date | Jan 28, 2026 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $37.38, which is an increase of 18.59% from the latest price.
News
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
The 3 Best Stocks to Invest $1,000 in Right Now
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising pr...
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen margins in the competitive generics market.
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.
3 Generic Drug Stocks to Watch Despite Industry Headwinds
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
Piper Sandler Updates Analyst Rating on TEVA, Raises Price Target | TEVA Stock News
Piper Sandler Updates Analyst Rating on TEVA, Raises Price Target | TEVA Stock News
Billionaire Stanley Druckenmiller Dumped 2 of His Top Performers -- Teva and Taiwan Semiconductor -- and Made This Sector-Based ETF His Fund's New No. 2 Holding
Form 13Fs help investors track which stocks and exchange-traded funds (ETFs) Wall Street's most successful money managers bought and sold in the latest quarter. Profit-taking looks to have been on bil...
Teva: Blackstone Life Sciences To Provide $400 Mln To Support Development Of Duvakitug
(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA) and funds managed by Blackstone Life Sciences announced a $400 million strategic funding agreement spread ac...
Teva Pharmaceutical (TEVA) Secures $400M Funding for Duvakitug Development
Teva Pharmaceutical (TEVA) Secures $400M Funding for Duvakitug Development
Blackstone (BX) Commits $400M to Teva for Duvakitug Development
Blackstone (BX) Commits $400M to Teva for Duvakitug Development
Teva Pharmaceutical Industries Ltd (TEVA) Shares Gap Down to $32.22 on Mar 3
Teva Pharmaceutical Industries Ltd (TEVA) Shares Gap Down to $32.22 on Mar 3
Baron Health Care Fund Q4 2025 Contributors And Detractors
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com...
Eliyahu Kalif Sells 345,810 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Eliyahu Kalif Sells 345,810 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
The Best Healthcare Stock to Invest $1,000 in Right Now
Teva Pharmaceutical Industries has more than doubled in price over the past year. The Israeli drugmaker, formerly known for producing generics, has made a major move into the specialty drugs space.
What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd?
Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) short interest as a percent of float has fallen 4.82% since its last report. According to exchange reported data, there are now 36.64 million shares ...
Here's Why I Won't Touch Teva Pharmaceutical With a 10‑Foot Pole
Teva Pharmaceutical Industries is a large manufacturer of generic drugs. The company is working to expand into more complex generics and to develop its own drugs.
Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors
Investor attention turned more intensely to the scale, timing, and funding of AI-related capital commitments, prompting renewed debate about whether expectations were running ahead of eventual monetiz...
Teva to Present at the Upcoming Investor Conferences in March
PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will ...
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application
Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) on Friday announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for olanzapine extended-release injec...
Teva (TEVA) Advances Schizophrenia Treatment with FDA Application
Teva (TEVA) Advances Schizophrenia Treatment with FDA Application
FDA Accepts NDA For Teva And Medincell's Olanzapine LAI In Schizophrenia Treatment
(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), together with Medincell, announced that the U.S. Food and Drug Administration (FDA) has accepted its...
Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application
Teva (TEVA) Gains FDA Nod for Schizophrenia Treatment Application
U.S. Food and Drug Administration (FDA) Accepts Teva's New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-'749) for the Once-Monthly Treatment of Schizophrenia in Adults
PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...
Price Over Earnings Overview: Teva Pharmaceutical Indus
In the current market session, Teva Pharmaceutical Indus Inc. (NYSE: TEVA) stock price is at $34.97, after a 2.32% drop. However, over the past month, the company's stock went up by 5.42% , and in th...